140 related articles for article (PubMed ID: 38567606)
21. HEK293T Cells Are Heterozygous for CCR5 Delta 32 Mutation.
Qi C; Jia X; Lu L; Ma P; Wei M
PLoS One; 2016; 11(4):e0152975. PubMed ID: 27042825
[TBL] [Abstract][Full Text] [Related]
22. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation.
Galvani AP; Novembre J
Microbes Infect; 2005 Feb; 7(2):302-9. PubMed ID: 15715976
[TBL] [Abstract][Full Text] [Related]
23. Is the European spatial distribution of the HIV-1-resistant CCR5-Delta32 allele formed by a breakdown of the pathocenosis due to the historical Roman expansion?
Faure E; Royer-Carenzi M
Infect Genet Evol; 2008 Dec; 8(6):864-74. PubMed ID: 18790087
[TBL] [Abstract][Full Text] [Related]
24. Distribution of the HIV resistance CCR5-Delta32 allele among Egyptians and Syrians.
Salem AH; Batzer MA
Mutat Res; 2007 Mar; 616(1-2):175-80. PubMed ID: 17166523
[TBL] [Abstract][Full Text] [Related]
25. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes.
Stephens JC; Reich DE; Goldstein DB; Shin HD; Smith MW; Carrington M; Winkler C; Huttley GA; Allikmets R; Schriml L; Gerrard B; Malasky M; Ramos MD; Morlot S; Tzetis M; Oddoux C; di Giovine FS; Nasioulas G; Chandler D; Aseev M; Hanson M; Kalaydjieva L; Glavac D; Gasparini P; Kanavakis E; Claustres M; Kambouris M; Ostrer H; Duff G; Baranov V; Sibul H; Metspalu A; Goldman D; Martin N; Duffy D; Schmidtke J; Estivill X; O'Brien SJ; Dean M
Am J Hum Genet; 1998 Jun; 62(6):1507-15. PubMed ID: 9585595
[TBL] [Abstract][Full Text] [Related]
26. Distribution of CCR5-Delta32, CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3'A genetic polymorphisms in HIV-1 infected and uninfected patients in the west region of Cameroon.
Nkenfou CN; Mekue LC; Nana CT; Kuiate JR
BMC Res Notes; 2013 Jul; 6():288. PubMed ID: 23880174
[TBL] [Abstract][Full Text] [Related]
27.
Xu M
Cell Biosci; 2020; 10():48. PubMed ID: 32257106
[TBL] [Abstract][Full Text] [Related]
28. Mutations in C-C chemokine receptor type 5 (CCR5) in South African individuals.
Barmania F; Potgieter M; Pepper MS
Int J Infect Dis; 2013 Dec; 17(12):e1148-53. PubMed ID: 23911155
[TBL] [Abstract][Full Text] [Related]
29. The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe.
Libert F; Cochaux P; Beckman G; Samson M; Aksenova M; Cao A; Czeizel A; Claustres M; de la Rúa C; Ferrari M; Ferrec C; Glover G; Grinde B; Güran S; Kucinskas V; Lavinha J; Mercier B; Ogur G; Peltonen L; Rosatelli C; Schwartz M; Spitsyn V; Timar L; Beckman L; Parmentier M; Vassart G
Hum Mol Genet; 1998 Mar; 7(3):399-406. PubMed ID: 9466996
[TBL] [Abstract][Full Text] [Related]
30. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.
Smith MW; Dean M; Carrington M; Winkler C; Huttley GA; Lomb DA; Goedert JJ; O'Brien TR; Jacobson LP; Kaslow R; Buchbinder S; Vittinghoff E; Vlahov D; Hoots K; Hilgartner MW; O'Brien SJ
Science; 1997 Aug; 277(5328):959-65. PubMed ID: 9252328
[TBL] [Abstract][Full Text] [Related]
31. Designer Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV.
Almeida MJ; Matos A
Curr HIV Res; 2019; 17(5):306-323. PubMed ID: 31652113
[TBL] [Abstract][Full Text] [Related]
32. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
Khan A; Paneerselvam N; Lawson BR
Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population.
Takácová M; Nogová P; Hábeková M; Staneková D
Acta Virol; 2008; 52(4):261-4. PubMed ID: 19143484
[TBL] [Abstract][Full Text] [Related]
34. Killing two birds with one stone: CRISPR/Cas9 CCR5 knockout hematopoietic stem cells transplantation to treat patients with HIV infection and hematological malignancies concurrently.
Au TY; Arudkumar J; Assavarittirong C; Benjamin S
Clin Exp Med; 2023 Dec; 23(8):4163-4175. PubMed ID: 37500934
[TBL] [Abstract][Full Text] [Related]
35. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1.
Zhang L; He T; Huang Y; Chen Z; Guo Y; Wu S; Kunstman KJ; Brown RC; Phair JP; Neumann AU; Ho DD; Wolinsky SM
J Virol; 1998 Nov; 72(11):9307-12. PubMed ID: 9765480
[TBL] [Abstract][Full Text] [Related]
36. Distribution of four HIV type 1-resistance polymorphisms (CCR5-Delta32, CCR5-m303, CCR2-64I, and SDF1-3'A) in the Bahraini population.
Salem AH; Farid E; Fadel R; Abu-Hijleh M; Almawi W; Han K; Batzer MA
AIDS Res Hum Retroviruses; 2009 Oct; 25(10):973-7. PubMed ID: 19803715
[TBL] [Abstract][Full Text] [Related]
37. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
Hütter G; Nowak D; Mossner M; Ganepola S; Müssig A; Allers K; Schneider T; Hofmann J; Kücherer C; Blau O; Blau IW; Hofmann WK; Thiel E
N Engl J Med; 2009 Feb; 360(7):692-8. PubMed ID: 19213682
[TBL] [Abstract][Full Text] [Related]
38. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
Allers K; Schneider T
Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
[TBL] [Abstract][Full Text] [Related]
39. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene.
Quillent C; Oberlin E; Braun J; Rousset D; Gonzalez-Canali G; Métais P; Montagnier L; Virelizier JL; Arenzana-Seisdedos F; Beretta A
Lancet; 1998 Jan; 351(9095):14-8. PubMed ID: 9433423
[TBL] [Abstract][Full Text] [Related]
40. A CRISPR-Cas Cure for HIV/AIDS.
Hussein M; Molina MA; Berkhout B; Herrera-Carrillo E
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
